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Abstract
Background: Numerous trials have demonstrated high efficacy and safety of artemisinin-based
combination therapy (ACT) under supervised treatment. In contrast, effectiveness studies
comparing different types of ACT applied unsupervised are scarce. The aim of this study was to
compare effectiveness, tolerability and acceptance of artesunate plus amodiaquine (ASAQ) against
that of artemether-lumefantrine (AL) in Ghanaian children with uncomplicated Plasmodium
falciparum malaria.
Methods: A randomized open-label trial was conducted at two district hospitals in the Ashanti
region, Ghana, an area of intense malaria transmission. A total of 246 children under five years of
age were randomly assigned to either ASAQ (Arsucam®) or AL (Coartem®). Study participants
received their first weight-adjusted dose under supervision. After the parent/guardian was advised
of times and mode of administration the respective three-day treatment course was completed
unobserved at home. Follow-up visits were performed on days 3, 7, 14 and 28 to evaluate clinical
and parasitological outcomes, adverse events, and haematological recovery. Length polymorphisms
of variable regions of msp1 and msp2 were determined to differentiate recrudescences from
reinfections. Acceptance levels of both treatment regimens w e r e  a s s e s s e d  b y  m e a n s  o f
standardized interviews.
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Results: Adequate clinical and parasitological responses after AL and ASAQ treatment were
similar (88.3% and 91.7%, respectively). Interestingly, more late clinical failures until day 28
occurred in AL-treated children than in those who received ASAQ (17.5% and 7.3%, respectively;
Hazard Ratio 2.41, 95% CI 1.00–5.79, p < 0.05).
Haematological recovery and drug tolerability were not found to be significantly different in both
study arms. The acceptance of treatment with ASAQ was higher than that with AL (rank-scores
10.6 and 10.3, respectively; p < 0.05).
Conclusion:  Unobserved AL and ASAQ treatment showed high adequate clinical and
parasitological responses, though AL was inferior in preventing late clinical failures.
Background
Artemisinin-based combination therapy (ACT) is advo-
cated as the way forward in antimalarial treatment to over-
come the global spread of Plasmodium falciparum drug
resistance [1]. ACT rapidly diminishes parasite biomass
leading to clinical and parasitological cure while at the
same time gametocytocidal activity might be able to
reduce overall malaria transmission [2]. Initially, efficacy
and safety of ACT had been evaluated in Southeast Asia
[3], and only recently, data became available from rand-
omized clinical trials in sub-Saharan Africa, where the
highest malaria burden occurs in children under five years
of age [4]. Based on recommendations of the World
Health Organization (WHO), several sub-Saharan coun-
tries introduced ACT as first-line treatment for uncompli-
cated malaria, although the comparatively high costs of a
treatment dose are a burden to their health systems [5].
Currently, artemether-lumefantrine (AL) and artesunate
plus amodiaquine (ASAQ) are the only widely available
drugs, which are produced on a large scale complying
with good manufacturing practices (GMP).
In 2004 Ghana implemented ASAQ as national first-line
treatment for uncomplicated P. falciparum malaria, after
experts had reviewed data on efficacy of chloroquine
(CQ) indicating widespread CQ resistance throughout the
country [6]. At that time, limited data on the efficacy and
safety of ASAQ and AL were available from sub-Saharan
Africa [7,8]. Subsequently, overdosing of locally produced
prepacked ASAQ for use in adults resulted in severe toxic-
ity in several cases and fuelled the call for alternative drugs
with better tolerability, e.g. assumed for AL. Clinical trials
in Uganda showed high efficacy and good tolerability of
AL when used as a six-dose therapy for uncomplicated
malaria in children, with a risk of treatment failure due to
recrudescence of less than 2% [9,10]. The high cure rates
of AL were confirmed in studies from Tanzania [11-13],
suggesting that this combination is still effective in areas
with considerable resistance to other antimalarial drugs.
However, despite the promising results of AL, there are
substantial limitations of this regimen, including the
twice-daily dosing schedule, the preferable administration
with fatty food, and selection for drug-resistant parasites.
Although adequate clinical and parasitological responses
in Ugandan children following unsupervised treatment
were similar to supervised treatment, other studies
showed that unsupervised therapy with AL resulted in
lower plasma levels of lumefantrine with an increased risk
for early reinfection [9,10].
The aim of this study was to compare the effectiveness,
tolerability and acceptance of unsupervised AL to that of
unsupervised ASAQ in an area of intense malaria trans-
mission in Ghana.
Methods
Study sites and participants
This randomized, open-label trial was conducted between
October, 2006 and September, 2007 at two district hospi-
tals within the Ashanti region of Ghana, the Child Welfare
Clinic of the Agogo Presbyterian Hospital, Asante Akim
North district, and the outpatient department of Agona
Government Hospital, Afigya Sekyere district. At both
sites, the predominant ethnic group is Ashanti, minorities
are Fanti, Ewe, Ga and Dagomba.
The majority of the population subsists on small-scale
crop farming, notably trading in general goods also plays
an important role. The vegetation in the study area is
partly tropical woodland, partly savanna. The area is clas-
sified as holoendemic and malaria transmission occurs
perennial with seasonal peaks [14]. The predominant spe-
cies is P. falciparum and the principal vectors are mosqui-
toes of the Anopheles gambiae complex and A. funestus.
According to annual reports of the District Health Direc-
torate more than 20% of hospital consultations are attrib-
uted to malaria, and malaria-related mortality is reported
to be around 25% in children less than five years of age.
Ownership of insecticide-treated bednets (ITNs) in the
region was reported to be only 1.6%, but subsidizing and
education programmes are ongoing [15].Malaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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Study procedures
Children aged 6–59 months with measured axillary body
temperature ≥ 37.5°C and/or history of fever within the
previous 24 hours presenting at the hospitals were ini-
tially seen by the study physician. After obtaining capillary
blood samples, thick and thin blood films were prepared,
and Diff-Quik® (Dade-Behring, Switzerland) stained thick
films were microscopically examined for the presence of
malaria parasites. Parents/guardians of slide-positive chil-
dren with P. falciparum monoinfection, a parasite density
between 2,000 and 200,000 asexual parasites/μl, and
without signs of severe malnutrition (weight-for-age < -3
SD of the median of the WHO child growth standard) or
any other severe underlying disease were asked to partici-
pate in the study if they were permanent residents in the
area.
Further inclusion criteria were 1) absence of general dan-
ger signs or signs of severe malaria according to WHO
[16], 2) no intake of antibiotics and no adequate antima-
larial treatment within the previous 7 days, 3) absence of
a history of hypersensitivity to any of the study drugs, 4)
ability to tolerate oral therapy, and 5) informed consent
provided by a parent/guardian. Before enrolment, the
aims and procedures of the study were explained to the
parent/guardian and his/her understanding was con-
firmed by interview before written or, in case of illiteracy,
thumb-printed consent was obtained in the presence of
an unbiased witness.
Children were randomly assigned to receive either ASAQ
or AL. Before drug application a venous blood sample was
taken to measure leukocyte counts as indicator for a bac-
terial co-infection. Treatment allocation was based on a
computer-generated list with randomization of individu-
als in blocks of ten.
Co-blister packed ASAQ [Arsucam® (50 mg AS/white tab-
let and 153 mg AQ/yellow tablet), Sanofi-Aventis, Paris,
France] were given weight-adjusted [5 – <10 kg (AS 1/2
tablet + AQ 1/2 tablet), 10 – <21 kg (AS 1 tablet + AQ 1
tablet), and 21 – <40 kg (AS 2 tablets + AQ 2 tablets] once
daily for 3 days, as recommended by the manufacturer.
AL [Coartem® (20 mg artemether/120 mg lumefantrine
fixed-dose combination tablets), Novartis, Basel, Switzer-
land] were administered twice daily as three-day, six-dose
regimen according to body weight [5 – <15 kg (1 tablet),
15 – <25 kg (2 tablets), or 25 – <35 kg (3 tablets)], the sec-
ond dose 8 hours after the first dose, according to manu-
facturer guidelines.
After enrolment, evaluation and consenting, participating
children received the first dose of the individually allo-
cated treatment (in sealed and numbered, opaque enve-
lopes) directly observed by a study nurse in a separate
cabinet, while study physicians were blinded to treatment
allocation. Prior to administration the tablets were
crushed and mixed with water.
Treated children were observed for 30 minutes and the
dose was readministered if vomiting occured. Children
who repeatedly vomited their first dose of study medica-
tion were referred for alternative management. Subse-
quently, the treatment schedule was explained to the
parents, who were strongly encouraged to resume normal
diet and give the study medication with fat-containing
food or during nursing if the participating child was
breastfed. The three-day treatment course was then com-
pleted at home.
Children received paracetamol for treatment of febrile
symptoms. Those with haemoglobin concentrations of
less than 10 g/dl received ferrous sulfate, folic acid and
anthelmintic treatment (if appropriate) according to
national guidelines.
Participants were asked to attend regular follow-up visits
on days 3, 7, 14, 28. Except for day 3, postponement of
one day was tolerated. Parents/guardians were encour-
aged to come to the clinic whenever a child felt sick, and
to return immediately to the hospital in case danger signs
and/or deterioration of the clinical status were observed
during treatment, or in case a treatment dose was vom-
ited.
Study participants were visited actively at home by mem-
bers of the study team and taken to the clinic if absent on
a scheduled visit day. On each visit a standardized medi-
cal history and medical examination Case Report Form
was completed. Capillary blood was obtained by finger-
prick for thick and thin blood films, a drop of blood was
stored on filter paper (Whatman®, Kent, UK) and a photo-
metric measurement of haemoglobin (HemoCue® Ltd.,
Derbyshire, UK) was performed. Full blood counts of
venous blood samples were done with an automated hae-
matology analyzer on day 0 (Kx-21N, Sysmex® Europe
GmbH, Norderstedt, Germany). Blood smears were
stained with Giemsa and parasite densities were deter-
mined by counting asexual parasites per 200 white blood
cells (or 500, if the count was less than 10 parasites per
200 white blood cells), assuming a white blood cell count
of 8,000/μl. Smears were considered negative if no asexual
parasite was seen after review of at least 100 high-power
fields. Parasite species were determined by examination of
thin films. For quality control slides of >10% of the
enrolled patients were re-examined by a second micro-
scopist who was blinded for the patient number, day of
follow-up, and former microscopic results. After compar-
ing the new with the original outcome classifications, noMalaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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discrepancies were found. Children who did not tolerate
oral therapy (repeated vomiting after initial study drug
application), with mixed plasmodial infections, hyperpar-
asitaemia (>200,000 asexual parasites/μl), or leukocytosis
(>15,000 leukocytes/μl) were subsequently excluded
from the analysis.
Primary outcomes
Treatment outcomes were defined according to WHO
guidelines (2003) as early treatment failure (ETF): danger
signs or complicated malaria or failure to adequately
respond to therapy on days 0–3; late clinical failure (LCF):
danger signs or complicated malaria or fever/history of
fever in the previous 24 hours and parasitaemia on days
4–28 without previously meeting criteria for ETF; late par-
asitological failure (LPF): asymptomatic parasitaemia day
4–28 without previously meeting criteria for ETF or LCF;
and adequate clinical and parasitological response
(ACPR): absence of parasitaemia on day 28 without previ-
ously meeting criteria for ETF, LCF, or LPF [17]. All
patients classified as treatment failures received rescue
treatment with quinine (10 mg/kg three times daily for 7
days).
The primary effectiveness outcomes were the 28-day risks
of recurrent symptomatic malaria (ETF and LCF) and
recurrent parasitaemia (ETF, LCF and LPF), unadjusted
and adjusted by genotyping.
Parasite genotyping
Recrudescent infections were distinguished from reinfec-
tions by nested-PCR of the variable block 2 region of the
merozoite surface proteine-1 gene (msp-1, belonging to
the three allele families K1, MAD20 and RO33) and of the
polymorphic block 3 region of the merozoite surface pro-
teine-2 gene (msp-2, 3D7 and FC27 allelic families), after
extracting DNA from filter papers of paired samples (sam-
ples collected on day 0 and the day of failure) following
the manufacturer's boiling protocol. Subsequently, ampli-
con lengths were analysed by capillary electrophoresis
using a DNA analyzer (ABI Prism® 3100 Genetic Analyzer,
Applied Biosystems, CA, USA) with GeneMapper™ ID
software (BioType, Dresden, Germany) as described else-
where [14]. A recurrent parasitaemia was categorized as
reinfection if none of the msp1/msp2 amplicons in poly-
clonal infections had identical lengths. Accordingly, recru-
descence was defined as the presence of at least one msp1/
msp2 amplicon of identical length.
Secondary outcomes
Secondary outcome measures were the change in the
mean haemoglobin concentration from day 0 to day 28,
the comparative tolerability, and the acceptance of the
treatment regimen. The comparative tolerability was
assessed by the risk of occurrence of an adverse event (AE),
classified by means of the Division of Microbiology and
Infectious Diseases pediatric toxicity tables [18] as mild
(grade 1), moderate (grade 2), severe (grade 3), or serious
(grade 4, SAE). A serious adverse event was defined as any
AE resulting in death or in persistent or significant disabil-
ity/incapacity, being life-threatening, requiring hospitali-
zation or significant medical intervention to prevent
serious outcome. For each AE, causality was assessed as
recommended by the WHO [19].
Acceptance levels were assessed by asking the parents/
guardians three standardized questions about the study
treatment (after completion of the treatment course), i.e.
a) how they appraised the treatment schedule, b) how
they liked the packaging of the drug, and c) how they
found the administration of the drug. Answers were
scored with 1 point (difficult/bad), 2 (fairly difficult/fair),
3 (easy/good), or 4 (very easy/very good) points, and were
compared using rank sum tests.
Sample size
The sample size was calculated to get at least 90% power
to detect a 10% difference of the risk of treatment failure
(defined as the number of patients with clinical cure and
clearance of asexual P. falciparum parasitaemia without
subsequent PCR-confirmed recrudescence by day 28)
between the two study arms at a 5% significance level. A
cure rate of more than 95% in one of the two treatment
arms was anticipated. Expecting a dropout rate of not
more than 10%, the targeted number of participants in
each study arm was 228.
Data analysis
Data generated during the trial were recorded in the Case
Report Form (CRF) of the respective patient and timely
double-entered into two separate databases (4th Dimen-
sion®, 2004 version 8.0.4, 4D, Neufahrn, Germany) with
variable ranges and internal consistency controls before
files were locked. Final analyses were done with Stata/IC™
version 10.0 (StataCorp, College Station, TX, USA).
Per-protocol analysis included all patients who matched
all inclusion criteria, were properly randomized, had
received the study drugs according to the protocol, and for
whom data were available on the study end-point without
protocol violation during the follow-up time. Intention-
to-treat analysis comprised all randomized patients fulfill-
ing the inclusion criteria without repeated vomiting after
the first study drug administration. Characteristics of both
study arms were compared by contingency (χ2) and non-
parametric (Wilcoxon) tests, and for evaluation of the
acceptance questionnaires Wilcoxon rank-sum tests were
performed with scores allocated to the potential answers.
Cox regression was used to calculate ACPR, LCF andMalaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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occurrence of adverse events. P values < 0.05 were consid-
ered significant.
Ethical considerations
All clinical investigations were conducted according to the
principles of the Helsinki Declaration. The protocol was
approved by the Committee on Human Research Publica-
tions and Ethics of the School of Medical Sciences of the
Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana, and the Ethics Committee of the Medical
Association Hamburg, Germany. In addition to the imme-
diate notification of SAEs, all AEs were reported on a
monthly basis to the data and safety monitoring board
(DSMB). An experienced clinical trial monitor audited the
trial that was registered at http://www.ClinicalTrials.gov
(NCT00374205).
Results
Baseline data and participant flow
The study started in October 2006 and was stopped in
September 2007. At that time, a total of 776 children were
screened and 246 were randomized (Figure 1). Adjusted
and unadjusted treatment outcome was available for 217
children in the intention-to-treat (ITT) and for 199 chil-
dren in the per-protocol (PP) analysis. There was no sig-
nificant difference in baseline characteristics of the two
treatment groups (Table 1). After initial randomization 9
children were excluded due to repeated vomiting of the
study drugs (they subsequently received alternative ther-
apy). According to the study protocol, another 20 individ-
uals had to be excluded from analysis because of the
detection of >200,000 asexual parasites/μl in the Giemsa-
stained thick film, or of non-falciparum parasites, or of
leukocyte counts >15,000/μl (Figure 1).
Primary effectiveness outcome
No ETF was observed. Adequate clinical and parasitologi-
cal responses were similarly high in both treatment
groups (Table 2). The per-protocol Kaplan-Meier survival
curves are displayed in Figure 2. However, LCF rates by
day 28 were significantly higher in AL-treated children
than in ASAQ-treated children in both, the per-protocol
analysis (17.5% and 7.3%, respectively; Hazard Ratio
2.41, 95% CI 1.00–5.79, p < 0.05; Figure 3) and in the
intention-to-treat analysis (16.5% and 6.5%, respectively;
HR 2.44, 95% CI 1.02–5.85, p < 0.05). A trend towards
higher LCF rates was also seen after exclusion of reinfec-
tions (Table 2).
Secondary effectiveness outcome
Haematologic recovery
Until September 2007, more than 50% of the study par-
ticipants developed anemia with haemoglobin values that
were classified as AEs after day 0. Therefore, in agreement
with the study protocol, the DSMB recommended the dis-
continuation of the trial. The final analysis showed that
haemoglobin levels on day 0 were not different in both
treatment arms, and haematologic recovery by day 28 was
adequate and similar after AL and after ASAQ treatment
[mean increase of haemoglobin AL group: 1.17 g/dl (95%
CI 0.82–1.53); ASAQ group: 1.38 g/dl (95% CI 1.00–
1.75); p = 0.44].
Tolerability
Both study drugs were well tolerated, and no drug-related
SAE occurred during the study. There were four SAEs (two
in each treatment arm, all were classified as "unlikely
related to treatment"), i.e. one was a mild acute asthmatic
attack on day 28, one a febrile convulsion on day 1, one
Table 1: Baseline characteristics of randomized study participants
Characteristic ASAQ AL p valuea
n = 123 n = 123
Patients, n (percentage)
Agogo site 41 (33.3%) 39 (31.7%) 0.785
Agona site 82 (66.7%) 84 (68.3%)
Sex (male: female), n 68: 55 65: 58 0.701
Age, months (SD) 32.1 (± 16.1) 30.7 (± 13.7) 0.458
Weight-for-ageb, z-score (SD) -0.93 (± 1.2) -0.81 (± 1.1) 0.414
Axillary temperature,°C (SD) 38.1 (± 0.98) 38.0 (± 1.1) 0.891
Parasite densityc,/μl 38864 34255 0.572
Haemoglobin, g/dl (SD) 9.9 (± 1.9) 9.6 (± 1.7) 0.133
Please note:
Data are mean values (SD), unless otherwise indicated.
a Determined using Wilcoxon test or χ2 test. None of the parameters in both study arms was significantly different.
b According to the WHO child growth standards. http://www.who.int/childgrowth/standards/weight_for_age/en/index.html
c Geometric mean; parasite densities were determined from Giemsa-stained thick blood films.
ASAQ, artesunate plus amodiaquine; AL, artemether-lumefantrine
SD, standard deviationMalaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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Trial profile Figure 1
Trial profile.Malaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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child received concomitant treatment for suspected enter-
itic bacterial coinfection on day 3 and one child was
extensively monitored due to a measured haemoglobin
level of 4.8 g/dl on day 3 but subsequently needed no
blood transfusion. Adverse events of grade 1–3 were,
regarding their nature, severity, and relation to the study
drug, similarly distributed in the study groups (Table 3).
Acceptance
More parents/guardians in the ASAQ group described the
treatment schedule as being very easy to apply, as com-
pared to those of the AL group (77.4% and 55.5%, respec-
tively; Wilcoxon test, p < 0.0005). This resulted in a
slightly higher overall rank-score for ASAQ, compared to
AL (10.6 and 10.3, respectively; p < 0.05), although pack-
aging and administration of the study drugs were
appraised similarly positive in both groups (see addi-
tional file 1 for the original questions and data used to
perform this analysis).
On inquiry, almost all parents/guardians quoted that they
would follow the same type of treatment again or advise a
friend or family member to use the respective drug.
Discussion
In this randomized effectiveness trial from Ghana cure
rates of ASAQ and AL for the treatment of uncomplicated
falciparum malaria were around 90%, qualifying both
ACTs as highly effective in children. LCFs until day 28
uncorrected and, as a trend, corrected for reinfections
were more frequently observed in AL-treated children
than in ASAQ-treated individuals. This observation of
similar ACPRs but higher LCFs after treatment with AL,
could reflect a difference in the prevention of recurrent
clinical malaria episodes between the two ACTs.
One limitation of the study is its premature termination
due to the high frequency of anemia cases (>50%). The
discontinuation was necessary through the stopping rules
of the study protocol despite the fact that the occurrence
of anemia was not different in both study arms and was
not related to treatment. Accordingly, the analysis was
performed with a decreased number of study participants
providing a power of 65% to detect differences between
the study arms. Therefore, the lack of a significantly differ-
ent effectiveness in one of the study arms has to be inter-
preted with caution. Nevertheless, cure rates could be
Table 2: Primary treatment outcomes
Treatment
Outcome ASAQ AL Hazard ratio
(95% CI)
p valuea
Per protocolb n = 96 n = 103
Recurrent parasitaemia 15 (15.6%) 23 (22.3%) 1.49 (0.77–2.87) 0.233
Recurrent parasitaemia (PCR corrected) 7 (7.3%) 12 (11.7%) 1.71 (0.67–4.38) 0.265
ETF 0 0
LCF 7 (7.3%) 18 (17.5%) 2.41 (1.003–5.79) 0.049
LCF (PCR corrected) 3 (3.1%) 10 (9.7%) 3.25 (0.89–11.92) 0.075
LPF 8 (8.3%) 5 (4.9%) 0.64 (0.21–1.99) 0.443
LPF (PCR corrected) 4 (4.2%) 2 (1.9%) 0.52 (0.09–2.87) 0.452
ACPR 81 (84.4%) 80 (77.7%) 0.96 (0.70–1.31) 0.792
ACPR (PCR corrected) 88 (91.7%) 91 (88.3%) 1 (0.74–1.34) 0.986
Intention to treatc n = 108 n = 109
Recurrent parasitaemia 15 (13.9%) 23 (21.1%) 1.51 (0.78–2.90) 0.218
Recurrent parasitaemia (PCR corrected) 7 (6.5%) 12 (11.0%) 1.72 (0.67–4.41) 0.256
ETF 0 0
LCF 7 (6.5%) 18 (16.5%) 2.44 (1.02–5.85) 0.046
LCF (PCR corrected) 3 (2.8%) 10 (9.2%) 3.27 (0.89–11.96) 0.073
LPF 8 (7.4%) 5 (4.6%) 0.66 (0.21–2.04) 0.409
LPF (PCR corrected) 4 (3.7%) 2 (1.8%) 0.53 (0.10–2.94) 0.468
ACPR 88 (81.5%) 86 (78.9%) 0.96 (0.71–1.30) 0.813
ACPR (PCR corrected) 95 (88.0%) 97 (89.0%) 1.00 (0.75–1.33) 0.988
Please note:
a Tested by Cox regression.
b Included were all patients who matched the inclusion criteria without violating the protocol.
c Included were all patients who matched all inclusion criteria without repeated vomiting after the first study drug administration.
CI, convidence interval; ASAQ, artesunate plus  amodiaquine;  AL, artemether-lumefantrine; ETF, early treatment failure;  LCF, late clinical failure; 
LPF, late parasitological failure; ACPR,  adequate clinical and parasitological responseMalaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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provided within the given confidence intervals and the
findings of different LCFs in both arms are valid inde-
pendent of the estimated power.
Another limitation of the study is the restriction of the fol-
low-up period to 28 days bearing the risk of underestima-
tion of treatment failures. Although logistically difficult,
only longitudinal clinical trials with follow-up time over
several months are appropriate for comparing the benefits
and risks of different antimalarial drugs, especially in
highly endemic areas [20]. Recently, an efficacy trial com-
paring ASAQ and AL was performed in Ghana with a fol-
low-up time of one whole year showing high day-28
ACPRs of 95.3% and 94.2%, respectively, with no differ-
ence in the occurrence of reinfections or adverse events
[21]. However, the differentiation between reinfection
and resistance is even more difficult with increasing fol-
low-up periods.
With respect to the interpretation of PCR-controlled cure
rates, it has to be considered, that the definition of reinfec-
tions is critical for the assessment of drug efficacy and
effectiveness. In the study presented here, a recrudescence
was defined as a recurrent P. falciparum parasitaemia with
detection of at least one msp1/msp2 amplicon of identical
length within the 28-day follow-up period compared to
amplicons found on day 0. This definition was chosen
very stringent to identify all possible treatment failures.
Remarkably, although most infections in our study area
are multiclonal and the genetic diversity is high [14],
some amplicons occur at high frequency. In principle, this
increases the likelihood that amplicons with identical
lengths were found in reinfections, leading to an overesti-
mation of recrudescences and, consequently, treatment
failures. Recently, the pitfalls of different genotyping
approaches in antimalarial drug trials were analysed in
relation to the transmission intensity [22]. The authors
concluded that, especially regarding high endemicity set-
tings, methods to overcome the inaccuracy of genotyping
to distinguish recrudescenses from new infections were
limited and complex, and comparative results should be
interpreted, rather to rely on the absolute efficacy of a
respective drug. But not only treatment efficacy, also post-
treatment prophylaxis is of major concern in areas of
intense malaria transmission, where timely recurrent
symptomatic malaria episodes require re-treatment, and
subsequently influence the acquisition of immunity and
increase the risk of development of drug resistance [23].
In accordance with these assumptions and in addition to
the study mentioned above a recent comparative efficacy
study in Ghanaian children showed lower parasitological
and clinical failure rates in the ASAQ compared to the AL
arm [24]. Another trial from Ghana showed a high PCR-
corrected efficacy of ASAQ and AL of 100% and 97.5%,
Kaplan-Meier survival curve of adequate clinical and parasito- logical response (ACPR) Figure 2
Kaplan-Meier survival curve of adequate clinical and 
parasitological response (ACPR). The figure shows the 
percentage of children with ACPR during the follow-up time 
of 28 days (in some plus 1 day) separated by treatment group 
according to the per-protocol analysis. The red line indicates 
children treated with artemether-lumefantrine (AL), the blue 
line indicates children treated with artesunate plus amodi-
aquine (ASAQ).
Kaplan-Meier failure curve of late clinical failures (LCF) Figure 3
Kaplan-Meier failure curve of late clinical failures 
(LCF). The figure shows the percentage of children with 
LCF during the follow-up time of 28 days (in some plus 1 
day) separated by treatment group according to the per-pro-
tocol analysis. The red line indicates children treated with 
artemether-lumefantrine (AL), the blue line indicates children 
treated with artesunate plus amodiaquine (ASAQ).Malaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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respectively [25]. Together with recently published effi-
cacy data the presented study shows that ASAQ is highly
efficacious, if not superior to AL, in treating uncompli-
cated malaria in Ghana.
These results are in contrast to most comparative efficacy
trials from Central and East Africa. In the Republic of
Congo, in Uganda and Tanzania including Zanzibar, AL
showed higher efficacy than ASAQ, especially a higher
potency in preventing reinfections [11-13,26-28]. In one
study from an area with holoendemic malaria transmis-
sion in Uganda, both regimens, ASAQ and AL, were highly
efficacious for clearance of infections but the risk of rein-
fection by day 42 was found to be high in both study
arms. In that study, although initial cure rates were above
90%, 66% of ASAQ-treated and only 50% of AL-treated
patients developed recurrent parasitaemia within 28 days
[28]. Only in Nigeria, one of a few West-African countries
from where data is available, the efficacies of ASAQ and
AL after supervised treatment were similarly high, with
PCR-corrected cure rates of 98.4% and 100%, respectively
[29], while uncorrected ACPRs were 87.0% and 82.5%,
respectively [30].
To explain the observed differences, one has to consider
that not only the prevalences of molecular markers for
ASAQ and AL drug resistance vary in different geographi-
cal regions [31,32], but also other parasite characteristics,
the genetic background of the host and multiple environ-
mental factors.
The lower effectiveness of AL in our trial compared to pre-
vious studies might be explained by unreliable or incor-
rect drug intake when unobserved. Furthermore,
intestinal absorption of lumefantrine, the long-acting
partner drug in AL, can be critically influenced by con-
comitant intake of fat-containing food [33]. Nevertheless,
the only other comparative effectiveness study performed
in Tanzania showed superiority of AL over ASAQ [11]. In
the present study, a fat-containing diet was emphatically
advised throughout, yet it forms a possible source of treat-
ment failure due to sub-therapeutic plasma drug concen-
trations. AL tablets need to be taken twice daily, with
equal number of tablets per dose. Therefore, skipping sin-
gle doses, not taking them entirely, or not coadminister-
ing fat-containing food could also have resulted in a
higher frequency of subtherapeutic drug levels in the AL
arm. Nevertheless, good compliance with AL treatment
seems to be possible, as shown in a trial on home manage-
Table 3: Adverse events
Type of adverse event ASAQ AL
n = 123 n = 123 OR p valuea
Vomiting of study drugs:
at least once 15 11 0.71 (0.31–1.61) 0.408
twice 6 3 0.49 (0.12–1.99) 0.318
n = 117 n = 120 RR p valueb
Deaths/hospitalizations 0 0
Anaemiac 82 78 0.90 (0.66–1.23) 0.511
Respiratory symptoms 27 25 0.90 (0.52–1.54) 0.692
Gastrointestinal symptoms 12 10 0.78 (0.34–1.81) 0.565
Dermatological symptoms 3 2 0.63 (0.10–3.76) 0.610
Other symptoms 2 2 0.95 (0.13–6.72) 0.956
Severity of adverse event
n = 117 n = 120 RR p valueb
Mild 57 46 0.72 (0.49–1.07) 0.104
Moderate 45 54 1.19 (0.80–1.77) 0.382
Severe 15 22 1.45 (0.75–2.79) 0.268
SAE 2 2 0.96 (0.13–6.80) 0.966
Please note:
Adverse events were classified by means of the Division of Microbiology and Infectious Diseases pediatric toxicity tables [18].
a Tested by logistic regression.
b Tested by Cox regression.
c Defined as Hb concentration <10 g/dl (age <2 years) and <11 g/dl (age >2 years).
ASAQ, artesunate plus amodiaquine; AL, artemether-lumefantrine; OR, odds ratio; RR, relative risk
SAE, serious adverse evenMalaria Journal 2008, 7:261 http://www.malariajournal.com/content/7/1/261
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ment of malaria in Ghana [34]. In Gabon, the outcome
after once-daily ASAQ treatment was significantly
improved by direct observation [35]. In this context, it
seems reasonable to hypothesize that the fixed-dose com-
bination of artesunate plus amodiaquine, which is cur-
rently replacing the co-blister packed ASAQ, will further
increase therapeutic adherence and treatment effective-
ness. Indeed, the acceptance of both ACTs was high and
only few caregivers reported general problems with the
study medications.
The trial was discontinued due to a high frequency of ane-
mia cases in our study population. Nevertheless, anemia
occurred equally often in both study arms and haemato-
logic recovery was similar and adequate in both arms. The
safety profiles of the study drugs were good and our find-
ings are in agreement with previous drug safety monitor-
ings in Senegal [36,37]. It is noteworthy that six ASAQ-
treated children and only three children in the AL arm had
to be excluded after repeated vomiting of the study drug.
Though not significant, this could be an indicator of a
poorer tolerability of ASAQ, which has also been shown
in a recently published trial from Ghana [24]. Pharmacok-
inetics after combined administration of artesunate and
amodiaquine, unlike the extensive investigations of AL,
were just recently systematically tested in fifteen healthy
volunteers [38]. Drug interactions, frequency and nature
of adverse events, namely severe transaminitis (n = 1),
neutropenia (n = 2), and hypersensitivity (n = 1), were
called a matter of concern. The risk of ASAQ-induced neu-
tropenia was reported to be increased in HIV-positive
individuals, especially when concomitantly treated with
antiretrovirals [39]. Therefore, despite its high efficacy,
ASAQ for combination therapy has to be carefully moni-
tored in areas with high HIV prevalence.
Conclusion
ASAQ and AL were both well tolerated and highly effective
for treatment of Ghanaian children with uncomplicated
falciparum malaria. Together with recent efficacy data, the
more effective prevention of LCFs after unobserved ASAQ
compared to AL treatment, affirms its appropriate role as
national first-line therapy in Ghana. Monitoring of effi-
cacy, safety, and drug resistance markers are essential to
guide national treatment policies, however, further com-
parative effectiveness studies of ACTs are needed in the
West African region.
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